Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 3Withdrawn 2Unknown 2Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 9Prostatic Neoplasms, Castration-Resistant 2Urogenital Neoplasms 1Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone 1Prostatic Diseases 1Neoplasms by Site 1Neoplasms 1Metastatic Castration-resistent Prostate Cancer 1Genital Neoplasms, Male 1Genital Diseases, Male 1Cushing Syndrome 1Adrenocortical Carcinoma 1

Interventions

Abiraterone Acetate 2enzalutamide 1cabazitaxel 1abiraterone 1Prednisone 1Photons 1Exome Sequencing 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Prostatic Neoplasms, Castration-Resistant × Abiraterone Acetate × Clear all
NCT05156450 2021-12-14

TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer

West China Hospital

Phase 2 Unknown
30 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT02254785 2017-12-06

Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer

British Columbia Cancer Agency

Phase 2 Unknown
120 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡